Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 40159 record(s)

Req # A-2024-000244

All communications to and from Breast Cancer Canada that are held by Health Canada from 2024-03-12 to 2024-05-30.

Organization: Health Canada

2 page(s)
August 2024

Req # A-2024-000251

The draft product monograph included in the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole from Jamp Pharma Corporation accepted into review in April 2024 and subsequently, included in the list of Generic submissions…

Organization: Health Canada

563 page(s)
August 2024

Req # A-2024-000252

The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Aripiprazole which was accepted into review in April 2024 and subsequently, included in the list of Generic submissions under review dated 2024-…

Organization: Health Canada

14 page(s)
August 2024

Req # A-2024-000258

The cover letter which accompanied the initial filing of the Abbreviated New Drug Submission (ANDS) for Tolvaptan which was accepted into review in November 2023 and, is included in the list of Generic submissions under review dated 2024-05-23 and…

Organization: Health Canada

34 page(s)
August 2024

Req # A-2024-000265

The most recent draft version and any existing feedback pertaining to the performance measurement evaluation for ethylene oxide, mentioned at this Uniform Resource Locator (URL) for greater clarity: https://www.canada.ca/en/health-canada/services/…

Organization: Health Canada

35 page(s)
August 2024

Req # A-2024-000416

The amount spent, per year, for art costs by your department/agency from January 1, 2016, to July 4, 2024.

Organization: Health Canada

100 page(s)
August 2024

Req # A-2020-001327

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-111903-527.

Organization: Health Canada

11 page(s)
August 2024

Req # A-2021-000627

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-111903-527.

Organization: Health Canada

11 page(s)
August 2024

Req # A-2022-000193

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-117704-138.

Organization: Health Canada

15 page(s)
August 2024

Req # A-2022-000561

Adverse Drug Reactions (ADRs). Report numbers: E2B_05405353, E2B_02538249, E2B_03902869, E2B_04601149, 000979193, 000985398, E2B_04893282, 000986091, E2B_00013096, 000980276.

Organization: Health Canada

245 page(s)
August 2024
Date modified: